CD8A and neoplasm: Additionally, TAMs inhibit the activation of CD8 + T cells through several strategies, including hindering their migration to the tumor, depleting crucial nutrients needed for T cell growth, emitting anti-inflammatory cytokines, and triggering checkpoints that inhibit T cell activity.